Gallacher Capital Management LLC Cassava Sciences Inc Transaction History

Gallacher Capital Management LLC

$216 Billion
Q2 2025

A detailed history of Gallacher Capital Management LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Gallacher Capital Management LLC holds 64,975 shares of SAVA stock, worth $142,295. This represents 0.05% of its overall portfolio holdings.

Number of Shares

64,975

Previous 69,660 6.73%

Holding current value

$142,295

Previous $104 Million 12.55%

% of portfolio

0.05%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 07, 2025	SELL	$1.19 - $2.24 $5,575 - $10,494	-4,685 Reduced 6.73%	64,975 $118 Million
Q1 2025 May 05, 2025	SELL	$1.5 - $3.02 $124,929 - $251,523	-83,286 Reduced 54.45%	69,660 $104 Million
Q4 2024 Feb 10, 2025	SELL	$2.29 - $32.18 $978,049 - $13.7 Million	-427,096 Reduced 73.63%	152,946 $361 Million
Q3 2024 Nov 12, 2024	SELL	$9.57 - $35.08 $23,408 - $85,805	-2,446 Reduced 0.42%	580,042 $17.1 Billion
Q2 2024 Aug 06, 2024	SELL	$12.35 - $26.11 $35,728 - $75,536	-2,893 Reduced 0.49%	582,488 $7.19 Billion
Q1 2024 May 06, 2024	BUY	$18.44 - $26.41 $69,611 - $99,697	3,775 Added 0.65%	585,381 $11.9 Billion
Q4 2023 Feb 06, 2024	BUY	$12.64 - $30.11 $47,804 - $113,876	3,782 Added 0.65%	581,606 $13.1 Billion
Q3 2023 Nov 13, 2023	SELL	$16.64 - $25.32 $90,987 - $138,449	-5,468 Reduced 0.94%	577,824 $9.61 Billion
Q2 2023 Aug 11, 2023	SELL	$21.59 - $27.88 $99,896 - $129,000	-4,627 Reduced 0.79%	583,292 $14.3 Billion
Q1 2023 May 12, 2023	SELL	$23.46 - $36.44 $14,404 - $22,374	-614 Reduced 0.1%	587,919 $14.2 Billion
Q4 2022 Jan 17, 2023	BUY	$27.82 - $44.16 $16.4 Million - $26 Million	588,533 New	588,533 $17.4 Billion

Others Institutions Holding SAVA

# of Institutions

155

Shares Held

15.7M

Call Options Held

1.67M

Put Options Held

1.26M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $87.8M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gallacher Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gallacher Capital Management LLC with notifications on news.

Account

Gallacher Capital Management LLC Cassava Sciences Inc Transaction History